The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study
Authors:
- 10 May 2021
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 238 (9) , 2393-2403
Abstract
Rationale Arginine vasopressin (AVP) is a neuropeptide that modulates both physiological and emotional responses to threat. Until recently, drugs that target vasopressin receptors (V1a) in the human central nervous system were unavailable. The development of a novel V1a receptor antagonist, SRX246, permits the experimental validation of vasopressin’s role in the regulation of anxiety and fear in humans. Objectives Here, we examined the effects of SRX246 in a proof-of-concept translational paradigm of fear (phasic response to imminent threat) and anxiety (prolonged response to potential threat). Methods Healthy volunteers received both SRX246 and placebo in a randomized, double-blind, counter-balanced order separated by a 5–7-day wash-out period. Threat consisted of unpleasant electric shocks. The “NPU” threat test probed startle reactivity during predictable threat (i.e., fear-potentiated startle) and unpredictable threat (i.e., anxiety-potentiated startle). Results As predicted, SRX246 decreased anxiety-potentiated startle independent of fear-potentiated startle. Conclusions As anxiety-potentiated startle is elevated in anxiety and trauma-associated disorders and decreased by traditional anxiolytics such as SSRIs and benzodiazepines, the V1a receptor is a promising novel treatment target.Keywords
Funding Information
- National Institutes of Health (ZIAMH002798)
- Azevan Pharmaceuticals Inc
This publication has 76 references indexed in Scilit:
- Relation Between Respiratory Sinus Arrythymia and Startle Response During Predictable and Unpredictable ThreatJournal of Psychophysiology, 2013
- Assessing fear and anxiety in humans using the threat of predictable and unpredictable aversive events (the NPU-threat test)Nature Protocols, 2012
- Acute Hydrocortisone Treatment Increases Anxiety but Not Fear in Healthy Volunteers: A Fear-Potentiated Startle StudyBiological Psychiatry, 2011
- Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs AnxietyNeuropsychopharmacology, 2009
- Increased Anxiety During Anticipation of Unpredictable Aversive Stimuli in Posttraumatic Stress Disorder but not in Generalized Anxiety DisorderBiological Psychiatry, 2009
- Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic reviewProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2009
- Prospective Prediction of Posttraumatic Stress Disorder Symptoms Using Fear Potentiated Auditory Startle ResponsesBiological Psychiatry, 2009
- Two-Week Treatment With the Selective Serotonin Reuptake Inhibitor Citalopram Reduces Contextual Anxiety but Not Cued Fear in Healthy Volunteers: A Fear-Potentiated Startle StudyNeuropsychopharmacology, 2008
- Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humansMolecular Psychiatry, 2008
- Vasopressin: Behavioral roles of an “original” neuropeptideProgress in Neurobiology, 2008